BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

About Afqlir® (aflibercept) The active ingredient in Afqlir® is aflibercept. Aflibercept is a recombinant fusion protein that binds to vascular endothelial growth factor A (VEGF-A) and placental ...

Opthea (ASX:OPT) has announced a boost to its cash reserves, receiving a $15.9m research and development tax incentive from ...

Study points to approach to improving anti-VEGF therapy for all wet AMD patients, and help subset of patients who lose vision ...

Merck & Co. has struck a licensing deal with LaNova Medicines that is potentially worth more than $3 billion to the clinical-stage biotechnology company.

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

in patients who failed therapy with drugs targeting vascular endothelial growth factor (VEGF). Sodhi and his colleagues ...

To combat this, doctors prescribe medications that slow the growth of new blood vessels, called anti-VEGF (vascular ...

Current treatments sometimes fail to help people with "wet" age-related macular degeneration -- and researchers now think ...

An RNA-editing gene therapy has been developed that switches off the key driver of common eye conditions affecting diabetics ...